Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADYNEX versus trastuzumab in HER2-positive metastatic breast cancer
IRCT20201223049810N1Phase 2Completed
- Sponsor
- Nano Daru
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Nano Daru. Primary endpoints: Objective response rate, Gastrointestinal disorders and 6 more. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20201223049810N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201223049810N1.